The efficacy of denosumab for prevention of early periprosthetic bone loss after cementless total hip arthroplasty

wbldb

Shao, Long¹; Wu, Xiang‐Dong²

J Bone Miner Res. May 2020;35(5):998-999

Cited Works (4)

Year	Entry
2019	Anastasilakis AD, Papapoulos SE, Polyzos SA, Appelman-Dijkstra NM, Makras P. Zoledronate for the prevention of bone loss in women discontinuing denosumab treatment: a prospective 2-year clinical trial. J Bone Miner Res. December 2019;34(12):2220-2228.
2017	McClung MR, Wagman RB, Miller PD, Wang A, Lewiecki EM. Observations following discontinuation of long-term denosumab therapy. Osteoporos Int. May 2017;28(5):1723-1732.
2017	Tsourdi E, Langdahl B, Cohen-Solal M, Aubry-Rozier B, Eriksen EF, Guañabens N, Obermayer-Pietsch B, Ralston SH, Eastell R, Zillikens MC. Discontinuation of denosumab therapy for osteoporosis: a systematic review and position statement by ECTS. Bone. December 2017;105:11-17.
2020	Nyström A, Kiritopoulos D, Ullmark G, Sörensen J, Petrén‐Mallmin M, Milbrink J, Hailer NP, Mallmin H. Denosumab prevents early periprosthetic bone loss after uncemented total hip arthroplasty: results from a randomized placebo‐controlled clinical trial. J Bone Miner Res. February 2020;35(2):239-247.